Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,751 questions in 147 reviews · Pain, Palliative and Supportive Care
current versionsNo studies 361 · 20.6%Ungraded 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Virtual reality distraction vs other VR distraction Acute pain intensity: observer‐report (during procedure) · children (0‐18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | NR | No studies |
Virtual reality distraction vs other VR distraction Acute pain intensity: behavioural measurement (observer‐report) (during procedure) · children (0‐18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | NR | No studies |
Virtual reality distraction vs other VR distraction Acute pain intensity: self‐report (post‐procedure) · children (0‐18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | NR | No studies |
Virtual reality distraction vs other VR distraction Acute pain intensity: observer‐report (post‐procedure) · children (0‐18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | NR | No studies |
Virtual reality distraction vs no distraction Acute pain intensity: observer‐report (during procedure) · children (0 to 18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | NR | No studies |
Virtual reality distraction vs other VR distraction Acute pain intensity: behavioural measurement (observer‐report) (post‐procedure) · children (0‐18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | NR | No studies |
Virtual reality distraction vs other VR distraction Adverse effects (related to engagement with VR) · children (0‐18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | NR | No studies |
Virtual reality distraction vs no distraction Acute pain intensity: behavioural measurement (observer‐report) (during procedure) · children (0 to 18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | 2 studies · 62 participants | Low |
Virtual reality distraction vs no distraction Acute pain intensity: self‐report (post‐procedure) · children (0 to 18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | 10 studies · 461 participants | Very low |
Virtual reality distraction vs no distraction Acute pain intensity: observer‐report (post‐procedure) · children (0 to 18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | 2 studies · 216 participants | Low |
Virtual reality distraction vs no distraction Acute pain intensity: behavioural measurement (observer‐report) (post‐procedure) · children (0 to 18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | 1 study · 42 participants | Very low |
Virtual reality distraction vs no distraction Adverse effects (related to engagement with VR) · children (0 to 18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | 5 studies · 154 participants | Very low |
Virtual reality distraction vs non‐VR distraction Acute pain intensity: self‐report (during procedure) · children (0 to 18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | 2 studies · 106 participants | Very low |
Virtual reality distraction vs non‐VR distraction Acute pain intensity: observer‐report (during procedure) · children (0 to 18 years) Virtual reality distraction for acute pain in children (2020) · Cochrane | no estimate extracted | 2 studies · 106 participants | Low |
Hospital‐based specialist palliative care vs usual care Patient health‐related quality of life (HRQoL)i, SD units(higher scores indicate better quality of life) · adults with advanced illness and their unpaid caregivers/families The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with… (2020) · Cochrane | no estimate extracted | 10 studies · 1344 participants | Low |
Hospital‐based specialist palliative care vs usual care Patient symptom burden · adults with advanced illness and their unpaid caregivers/families The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with… (2020) · Cochrane | no estimate extracted | 6 studies · 761 participants | Very low |
Hospital‐based specialist palliative care vs usual care Patient satisfaction with careiii, SD units(higher scores indicate better patient satisfaction) · adults with advanced illness and their unpaid caregivers/families The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with… (2020) · Cochrane | no estimate extracted | 2 studies · 337 participants | Low |
Hospital‐based specialist palliative care vs usual care Achieving patient preferred place of death (measured by number of patients with home death) · adults with advanced illness and their unpaid caregivers/families The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with… (2020) · Cochrane | OR 1.63 | 7 studies · 861 participants | Low |
Hospital‐based specialist palliative care vs usual care Painiv, SD units(lower scores indicate less pain) · adults with advanced illness and their unpaid caregivers/families The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with… (2020) · Cochrane | no estimate extracted | 4 studies · 525 participants | Very low |
Hospital‐based specialist palliative care vs usual care Unpaid caregiver burdenv · adults with advanced illness and their unpaid caregivers/families The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with… (2020) · Cochrane | no estimate extracted | 2 studies · 170 participants | Very low |
Hospital‐based specialist palliative care vs usual care Cost and cost‐effectiveness · adults with advanced illness and their unpaid caregivers/families The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with… (2020) · Cochrane | no estimate extracted | 13 studies · 2103 participants | Very low |
Pregabalin 300 mg vs placebo At least 30% pain intensity reduction · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 3 studies · 589 participants | Moderate |
Pregabalin 600 mg vs placebo Patient Global Impression of Change ‐ much or very much improved · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | NR | Very low |
Pregabalin 600 mg vs placebo Lack of efficacy withdrawal · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 4 studies · 732 participants | High |
Pregabalin 600 mg vs placebo Somnolence · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 4 studies · 732 participants | Moderate |
Pregabalin 600 mg vs placebo Dizziness · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 4 studies · 732 participants | Moderate |
Pregabalin 600 mg vs placebo Adverse event withdrawal · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 4 studies · 732 participants | High |
Pregabalin 300 mg vs placebo At least 30% pain intensity reduction · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 8 studies · 2320 participants | Moderate |
Pregabalin 300 mg vs placebo At least 50% pain intensity reduction · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 11 studies · 2931 participants | Moderate |
Pregabalin 300 mg vs placebo Patient Global Impression of Change ‐ much or very much improved · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 5 studies · 1050 participants | Moderate |
Pregabalin 300 mg vs placebo Patient Global Impression of Change ‐ very much improved · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 2 studies · 501 participants | Low |
Pregabalin 300 mg vs placebo Lack of efficacy withdrawal · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 10 studies · 2430 participants | High |
Pregabalin 300 mg vs placebo At least 50% pain intensity reduction · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 4 studies · 713 participants | Moderate |
Pregabalin 300 mg vs placebo Somnolence · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 12 studies · 3315 participants | Moderate |
Pregabalin 300 mg vs placebo Dizziness · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 12 studies · 3315 participants | Moderate |
Pregabalin 300 mg vs placebo Adverse event withdrawal · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 13 studies · 3384 participants | High |
Pregabalin 600 mg vs placebo At least 30% pain intensity reduction · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 3 studies · 789 participants | Moderate |
Pregabalin 600 mg vs placebo At least 50% pain intensity reduction · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 7 studies · 1360 participants | Moderate |
Pregabalin 600 mg vs placebo Patient Global Impression of Change ‐ much or very much improved · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 3 studies · 537 participants | Moderate |
Pregabalin 600 mg vs placebo Lack of efficacy withdrawal · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 5 studies · 879 participants | High |
Pregabalin 600 mg vs placebo Somnolence · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 7 studies · 1501 participants | Moderate |
Pregabalin 600 mg vs placebo Dizziness · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 8 studies · 1885 participants | Moderate |
Pregabalin 600 mg vs placebo Adverse event withdrawal · adults with moderate or severe pain associated with painful diabetic neuropathy Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 8 studies · 1669 participants | High |
Pregabalin 300 mg vs placebo Patient Global Impression of Change ‐ much or very much improved · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 3 studies · 568 participants | Low |
Pregabalin 300 mg or 600 mg vs placebo mg pregabalin · adults with moderate or severe neuropathic pain Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 300 participants | Ungraded |
Pregabalin 300 mg or 600 mg vs placebo At least 1 AE · adults with moderate or severe neuropathic pain Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 15 studies · 3697 participants | High |
Pregabalin 300 mg or 600 mg vs placebo Serious AE · adults with moderate or severe neuropathic pain Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 17 studies · 4112 participants | High |
Pregabalin 300 mg or 600 mg vs placebo mg pregabalin · adults with moderate or severe neuropathic pain Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 600 participants | Ungraded |
Pregabalin 300 mg vs placebo Lack of efficacy withdrawal · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 5 studies · 933 participants | High |
Pregabalin 300 mg vs placebo Somnolence · adults with moderate or severe pain associated with postherpetic neuralgia Pregabalin for neuropathic pain in adults (2019) · Cochrane | no estimate extracted | 5 studies · 933 participants | Moderate |